On June 1, 2022 Kinnate Biopharma Inc. (Nasdaq: KNTE) ("Kinnate"), a clinical-stage precision oncology company, reported that the company will participate in two upcoming in-person investor conferences (Press release, Kinnate Biopharma, JUN 1, 2022, View Source [SID1234615338]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Thursday, June 9 at 1:00 p.m. ET / 10:00 a.m. PT at the Jefferies Healthcare Conference. Neha Krishnamohan, chief financial officer and executive vice president, corporate strategy, will represent the company in a fireside chat at the conference.

Wednesday, June 15 at 1:00 p.m. ET / 10:00 a.m. PT at the Goldman Sachs 43rd Annual Global Healthcare Conference. Nima Farzan, chief executive officer, will represent the company in a fireside chat at the conference.
Members of the Kinnate management team will also host investor meetings during the conferences.

Investors and the general public are invited to listen to a live webcast of the session through the "Investors and Media" section on Kinnate.com. A webcast replay will be made available following the event for 30 days.